Ceftazidime-avibactam-based regimens for the treatment of central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae in a pediatric patient

Liming He; Wanzhen Li; Wei Cheng; Yixue Wang; Xiaofen Liu; Pan Fu; Chuanqing Wang; Junqi Zhang; Guoping Lu; Gangfeng Yan; Jing Zhang

doi:10.1016/j.jgar.2026.04.002

April 1, 2026Journal of Global Antimicrobial ResistanceOpen Access

Ceftazidime-avibactam-based regimens for the treatment of central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae in a pediatric patient

View Full Paper

Ask AI

Bookmark

Share

Key Points

To explore the pharmacokinetic and pharmacodynamic evidence of ceftazidime-avibactam for treating CNS infections in pediatric patients.
Assessment of ceftazidime-avibactam combined with intraventricular polymyxin B
Evaluation of effectiveness against carbapenem-resistant Klebsiella pneumoniae
Focus on pediatric population with CNS infections
Ceftazidime-avibactam shows potential effectiveness for treating pediatric meningitis caused by CRKP.
Combination therapy with polymyxin B may enhance therapeutic outcomes.
Emphasizes the need for further studies on dosing and long-term safety.

Implication

This report demonstrates the effectiveness of ceftazidime-avibactam for treating CNS infections in children, suggesting new therapeutic options.

Abstract

This report adds to the limited pharmacokinetic/pharmacodynamic (PK/PD) evidence for ceftazidime-avibactam in pediatric CNS infections. It also supports the potential role of ceftazidime-avibactam combined with intraventricular polymyxin B as a therapeutic option for CRKP meningitis in children. Further studies are needed to optimize dosing strategies and evaluate long-term safety in the pediatric population.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

He et al. (2026) studied this question.

synapsesocial.com/papers/69e07bc12f7e8953b7cbd5ff https://doi.org/10.1016/j.jgar.2026.04.002

View Full Paper

Ask AI

Bookmark

Share

Ceftazidime-avibactam-based regimens for the treatment of central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae in a pediatric patient

Key Points

Implication

Abstract

Discussion

Cite This Study

Ceftazidime-avibactam-based regimens for the treatment of central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae in a pediatric patient

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading